🩸 Subjective Cognitive Decline Risk Stratification Simulator

Subjective Cognitive Decline: Complaint Without Measurable Deficit

Placeholder: defining SCD as self-perceived decline with normal objective testing.

• ~25%: Prevalence 60+ (placeholder population estimate)
• ~6–8%: Annual conversion (placeholder MCI conversion rate)
• Normal: Testing sensitivity (placeholder neuropsych result)
• Memory: Symptom domain (placeholder most common complaint)

Defining the SCD construct

Placeholder text describing SCD diagnostic framework and criteria.

Distinguishing Normal Age-Related Change From Early Neurodegeneration

Placeholder: contrasting benign forgetfulness patterns with early pathological signs.

• Common: Benign forgetfulness (placeholder normative pattern)
• Progressive: Red-flag pattern (placeholder concerning trajectory)
• Key input: Informant report (placeholder corroboration source)
• Absent: Functional impact (placeholder SCD hallmark)

Normal aging benchmarks

Placeholder text on differentiating normative cognitive aging curves from disease.

Risk Factors That Raise Conversion Likelihood

Placeholder: cataloguing genetic, family, and clinical risk modifiers.

• Elevated risk: APOE4 carriers (placeholder genetic modifier)
• 2× risk: Family history (placeholder relative risk estimate)
• Additive: Vascular factors (placeholder comorbidity effect)
• Confounder: Depression history (placeholder overlapping symptom)

Stratifying by risk burden

Placeholder text describing cumulative risk factor scoring approach.

When to Consider Biomarker Testing

Placeholder: CSF, amyloid PET, and blood biomarker decision points.

• Available: CSF Aβ42/tau (placeholder biomarker modality)
• High cost: Amyloid PET (placeholder access constraint)
• Emerging: Blood biomarkers (placeholder plasma p-tau assay)
• Guides use: Pretest probability (placeholder testing threshold)

Biomarker decision criteria

Placeholder text on selecting candidates for biomarker workup.

Choosing Between Monitoring and Immediate Workup

Placeholder: final triage decision balancing risk and patient preference.

• 12 months: Routine follow-up (placeholder interval for low risk)
• 6 months: Enhanced monitoring (placeholder interval for moderate risk)
• Immediate: Urgent workup (placeholder high-risk pathway)
• Essential: Shared decision (placeholder patient involvement)

Final triage pathway

Placeholder text summarizing the monitoring-versus-workup decision tree.